The efficacy of posterior wall isolation in atrial fibrillation ablation: A systematic review and meta-analysis of randomized controlled trials

Chanavuth Kanitsoraphan MD1 | Pattara Rattanawong MD2 | Chol Techorueangwiwat MD1 | Jakrin Kewcharoen MD3 | Raktham Mekritthikrai MD4 | Narut Prasitlumkum MD5 | Parthav Shah MD1 | Hicham El Masry MD2

1 University of Hawaii Internal Medicine Residency Program, Honolulu, Hawaii, USA
2 Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA
3 Department of Medicine, Division of Cardiology, Loma Linda University Medical Center, Loma Linda, California, USA
4 Division of Cardiology, Cook County Hospital, Cook, Illinois, USA
5 Department of cardiology, University of California Riverside, Riverside, California, USA

Correspondence
Hicham El Masry, MD, Departments of Electrophysiology and Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, 85054, USA.
Email: elmasry.hicham@mayo.edu

Funding information
This research did not receive any specific grant from funding agencies in the public.

Abstract
Background: Posterior wall isolation (PWI) is an emerging approach in atrial fibrillation (AF) ablation, yet its efficacy remains controversial. This is the first meta-analysis of randomized controlled trials (RCT) to evaluate the efficacy of PWI in AF ablation.

Objective: To assess the efficacy of PWI in reducing atrial arrhythmia recurrence following initial AF ablation at long-term follow-ups when compared to conventional methods.

Methods: We conducted a literature search from inception through September 2021 in EMBASE and MEDLINE databases. We included RCTs that compared outcomes in PWI and conventional approaches of AF ablation. Data from each study were combined using the random-effects, generic inverse variance method of DerSimonian and Laird to calculate odds ratio (OR), and 95% confidence interval (CI).

Results: Eight RCT from 2009 to 2020, including 1024 AF patients, were included. PWI did not decrease overall atrial arrhythmias recurrence (RR 0.96, 95% CI:0.88–1.05, I² = 31.6%, p-value 0.393). However, the pooled analysis showed a significant decrease in AF recurrence in PWI compared to controlled approaches (RR 0.88, 95% CI:0.81–0.96, I² = 48.2%, p-value .004). In the subgroup analysis, PWI significantly decreased AF recurrence in the studies that included only persistent AF (RR = 0.89, 95% CI:0.80–0.98, I² = 65.2%, p-value .014). PWI significantly decreased AF recurrence when compared to PVI with roof line (RR 0.84, 95% CI 0.74–0.95, I² 0.00%, p-value .008).

Conclusion: Our study suggests that adding PWI significantly decreased AF recurrence in patients with persistent AF compared to controlled approaches. It highlights the importance of considering PWI during the initial procedure in this patient population.

Publisher’s note: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
1 | INTRODUCTION

AF ablation is an established treatment in patients with symptomatic atrial fibrillation (AF). Atrial fibrillation ablation, when compared to medication therapy, has been shown effective in reducing AF recurrence, symptomatic AF, and AF burden.\textsuperscript{1–4} The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement recommends catheter ablation for patients with symptomatic AF that is refractory or intolerant to at least one class I or III antiarrhythmic medication (Class I recommendation for paroxysmal AF [PAF], class IIa for persistent AF [PeAF], and class IIb for long-standing PeAF).\textsuperscript{5} Pulmonary vein isolation (PVI) has been a standard approach for AF ablation. Additional ablation targets have been proposed to improve outcomes; however, there has been no class I recommendations for routine additional ablation in conjunction with PVI.\textsuperscript{5} Posterior wall isolation (PWI) is a promising emerging technique to improve AF ablation efficacy, particularly in patients who tend to have higher recurrence rates. However, the technique has faced challenges regarding its efficacy and safety since previous studies showed inconsistent data.\textsuperscript{6} The current guideline suggested PWI might be considered in initial or repeat ablation in PeAF or long-standing PeAF (Class IIb).\textsuperscript{5} The STAR AF II trial suggested no benefits of additional lines performed beyond PVI in patients with PeAF.\textsuperscript{7} As more evidence on the efficacy of PWI emerges, this is the first meta-analysis of RCT to evaluate the efficacy of PWI in AF ablation.

2 | METHODS

2.1 | Search strategy

The professional librarian performed the literature search from the EMBASE, PubMed, Scopus, Web of Science, and Cochrane databases from inception to September 2021 using a search strategy that includes the term “atrial fibrillation,” “pulmonary vein isolation,” “posterior wall isolation,” and “box isolation”. We manually reviewed references from review articles and systematic reviews for additional studies. Only full articles in English and studies conducted in RCTs were included. The quality assessment and bias risk assessment of the selected studies were conducted.

2.2 | Inclusion and exclusion criteria

The eligibility criteria included the following.

1) Randomized control trial studies reporting endpoints of atrial fibrillation or atrial arrhythmia recurrence after AF ablation with or without PWI.
(2) Adjusted or unadjusted RR with 95% confidence interval, or adequate raw data for calculation were provided.

Study eligibility was independently determined by two investigators (CK and PR), and differences were resolved by mutual consensus. Studies with overlap or duplicated populations were excluded.

2.3 | Data extraction

The included studies were reviewed for the type of study, country of origin, type of AF, total population, mean age, PWI techniques and techniques in control arms, mean follow-up, the definition of recurrence, and conclusion. Extracted data were collected using standardized forms. Overall atrial arrhythmia was defined as the combination of AF, atrial flutter, or atrial tachycardia.

2.4 | Statistical analysis

We performed a meta-analysis of the included studies using a fixed-effect model. We pooled the point estimates of RR from each study using the generic inverse-variance method of Der Simonian and Laird. Heterogeneity was quantified using the I² statistics, which range from 0 to 100% and I² > 50% indicates substantial heterogeneity. Publication bias was assessed using a funnel plot, and Egger’s regression test with a p-value of <.05 was considered significant. All statistical analyses were performed using Stata version 14.2 TX: StataCorp; 2015.

3 | RESULTS

3.1 | Search results

Our search strategy yielded 763 potentially relevant articles (331 articles from EMBASE, 276 articles from PubMed, 78 from Scopus, 74 from Web of Science, and 4 from the Cochrane database). After the exclusion of duplicated articles, 600 articles underwent title and abstract review. At this stage, 567 articles were excluded as they were not randomized controlled trials, were not conducted in AF patients, or the titles and abstracts were not relevant. This left 33 articles for full-length review. A further 25 studies were excluded as they were overlap or duplicated patients’ populations or did not report outcomes and did not provide sufficient data to calculate RR. Therefore, a total of 8 studies were included in this meta-analysis. Figure 1 outlines the search and literature review process.

3.2 | Descriptions of included studies

Eight studies with a total of 1024 AF patients undergoing initial AF ablation were analyzed and included in this meta-analysis.8–16 Of these patients, 512 (50.0%) underwent PWI and 512 (50.0%) underwent controlled approaches. One hundred and seventy-eight (34.8%) undergoing PWI and 189 patients (36.9%) undergoing controlled approaches had atrial arrhythmia recurrence at follow-up. The characteristics of included studies are outlined in Table 1.

3.3 | Overall meta-analysis results

In the overall pooled analysis of 8 studies, PWI was not significantly associated with a decrease in overall atrial arrhythmia recurrences (RR 0.96, 95% CI 0.88–1.05, I² = 31.6%, p-value .393) (Figure 2). However, 6 of 8 studies8, 10, 12, 13, 15, 16 reported AF recurrence as an outcome, in which pooled analysis showed that PWI significantly decreased the risk of AF recurrence (RR 0.88, 95% CI 0.81–0.96, I² 48.4%, p-value .003) (Figure 3).

3.4 | Outcomes by type of AF

3.4.1 | Persistent AF

Four studies included a total of 547 PeAF patients undergoing initial AF ablation (273 PWI and 274 controlled approaches).8, 10, 12, 16 AF recurred in 59 patients (21.5%) undergoing PWI and 84 patients (30.3%) undergoing controlled approaches. Atrial arrhythmias recurred in 72 patients (26.3%) undergoing PWI and 92 patients (33.2%) undergoing a controlled approach. Pooled analysis demonstrated that PWI significantly decrease AF recurrences (RR 0.88, 95% CI 0.80–0.97, I² 65.5%, p-value .019) (Figure 3B) but did not decrease overall atrial arrhythmia recurrences (RR 0.91, 95% CI 0.81–1.01, I² 51.4%, p-value .073) in PeAF population (Figure 2B).

3.4.2 | Paroxysmal and persistent AF

Four studies involved 473 non-specific AF patients (included both PeAF and PAF) undergoing initial AF ablation (238 PWI and 235 controlled approaches).9, 13–15 Atrial arrhythmias recurred in 106 patients (39.6%) undergoing PWI and 97 patients (36.1%) undergoing the conventional approach. Pooled analysis demonstrated that PWI did not decrease AF recurrences (RR 0.87, 95% CI 0.75–1.02, I² 0.00%, p-value .090) (Figure 3B) as well as overall atrial arrhythmia recurrences (RR 1.05, 95% CI 0.91–1.22, I² 0.0%, p-value .515) (Figure 2B) in the non-specific population of AF.

3.5 | Outcomes by ablation approaches

3.5.1 | PWI versus PVI without roof line

Five studies including a total of 564 patients undergoing initial AF ablation (282 PWI and 282 PVI without roof line) reported
| First author, year | Country       | Institutions | Type of AF | N  | Posterior Wall isolation ablation technique |
|-------------------|---------------|--------------|------------|----|-------------------------------------------|
| Aryana, 2020      | Japan         | Japan Red Cross Yokohama-city Bay Hospital and Mercy General Hospital and Dignity Health Heart and Vascular Institute | PeAF/LSPe AF | 110 | CPVI (cryoballoon) + PWI (cryoballoon ablation of bounded by LA roof, left pulmonary vein, right pulmonary vein, and posterior inferior border) + CTI |
| Chilukuri, 2011   | USA           | The John Hopkins Hospital | PAF 79%, PeAF 21% | 30  | Single ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly |
| JS Kim, 2014      | Korea         | Korea University Guro Hospital | PeAF | 120 | CPVI (without interpulmonary isthmus line) + POBI (linear ablation along the roof and posterior inferior wall) + anterior wall of LA + CTI |
| Lee, 2019         | Korea         | Kyung Hee University Medical College, Korea University Cardiovascular Center, Ewha Womans University, Yonsei University Health System, and Hanyang University | PeAF | 217 | CPVI + POBI (linear ablation along the roof and posterior inferior wall) + CTI |
| Lim, 2012         | Australia, Singapore | Westmead Hospital (Australia), National University Hospital (Singapore), Liverpool hospital and University of New South Wales (Australia) | PAF, PeAF or longstanding AF | 220 | Single-ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly + CTI |
| Mun, 2012         | Korea         | Yonsei University Health System | PAF | 156 | CPVI + POBI (linear ablation along the roof and posterior inferior wall) |
### TABLE 1 Continued

| Control                                      | Mean follow up (months) | Recurrence definition                                                                 | Complications                                                                                           | Conclusion                                                                                     |
|----------------------------------------------|-------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| CPVI (cryoballoon) + CTI                     | 12                      | AF, AT, atrial flutter >30 seconds Method: ECG at each follow-up visit, 7-day to 14-day mobile cardiac telemetry monitoring at 3, 6, and 12 months post-ablation, unless a cardiac implantable electronic device existed. | PWI: 1 persistent phrenic nerve palsy, 1 bradycardia requiring pacemaker, 1 groin vascular complication  | PVI + PWI using cryoballoon is associated with a significant reduction in atrial fibrillation recurrence. |
| CPVI (without interpulmonary isthmus line)   | 10 ± 2                  | AF, AT, atrial flutter >30 seconds Method: Daily 30-second measurement of heart rhythm with the portable ECG monitoring device | PWI: 1 embolic stroke, 1 cardiac tamponade, 1 femoral arterial pseudoaneurysm, 1 abdominal wall hematoma  | The efficacy of box isolation is similar to circumferential PVI protocol for AF ablation.          |
| CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + anterior wall of LA + CTI | 12                      | AF or atrial flutter Method: ECG at every visit, 48-hour Holter monitoring at 1, 3, 6, and 12 months. | PWI: None                                                                                              | Additional POBI after anterior wall linear lesions and PVI can reduce AF recurrence in PeAF.    |
| CPVI + CTI                                   | 16.2 ± 8.8              | AF or AT >30 seconds Method: ECG at every visit and 24-hour Holter at 3 and 6 months and then every 6 months thereafter | PWI: 4 cardiac tamponades, 2 sinus node dysfunction, 1 atrioesophageal fistula, 3 pericarditis, 2 pseudoaneurysm | In patients with PeAF, an empirical POBI did not improve the rhythm outcome of the catheter ablation. |
| Wide antral isolation: CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + CTI | 24                      | AF, AT, atrial flutter >30 seconds Method: ECG or 7-day Holter at 6 and 12 months. | PWI: 1 cardiac tamponade, 2 ischemic stroke                                                                 | Single-ring isolation resulted in fewer AF recurrences than wide antral isolation, although organized AT and overall atrial arrhythmia recurrences were similar. |
| CPVI                                         | 15.6 ± 5.0              | AF or AT >30 seconds Method: ECG at every visit. 24-hour/ 48-hour and/or event recorder at 3, 6, and 12 months. | PWI: 3 pericarditis                                                                                     | Additional linear POBI ablations to CVPI did not improve clinical outcome.                      |
overall atrial arrhythmia recurrences.8, 9, 12, 14, 16 Three of which reported AF recurrences.8, 12, 16 Pooled analysis demonstrated that PWI did not decrease overall atrial arrhythmia recurrences (RR 0.98, 95% CI 0.88–1.08, I² 14.8%, p-value .657) (Figure 2A) or AF recurrences (RR 0.92, 95% CI 0.83–1.03, I² 65.3%, p-value .138) (Figure 2B).

3.5.2 | PWI versus PVI with roof line

Three studies including a total of 460 patients undergoing initial AF ablation (230 PWI and 230 PVI with roof line) reported overall atrial arrhythmia and AF recurrences.10, 13, 15 Pooled analysis demonstrated that PWI significantly decreased AF recurrences (RR 0.84, 95% CI 0.74–0.95, I² 0.0%, p-value .008) (Figure 3A), but did not decrease overall atrial arrhythmia recurrences (RR 0.94, 95% CI 0.81–1.10, I² 56.8%, p-value .445) (Figure 2A) when compared to PVI with roof line.

3.5.3 | Complications

There was no significant difference risk of vascular access (RR 1.02, 95% CI 0.99–1.04, I² 0.0%, p-value .222), pericardial effusion (RR 0.98, 95% CI 0.96–1.01, I² 0.0%, p-value .147), pericarditis (RR 1.02, 95% CI 0.99–1.04, I² 1.8%, p-value .240), and stroke or TIA (RR 1.00, 95% CI 0.97–1.03, I² 0.0%, p-value .950) between PWI and controlled approaches (Figure 4).

3.5.4 | Sensitivity analysis

We conducted a sensitivity analysis by excluding one study at a time to assess the stability of the results of the meta-analysis. None of the results were significantly altered in the overall analysis.

3.6 | Publication and risk study bias

We examined the contour-enhanced funnel plot of the included studies to investigate potential publication bias. No significant publication bias was observed on the funnel plot of overall atrial arrhythmias and AF; however, in the limitation of a small number of included study. (Figure 5A and Figure 5B, respectively). Meanwhile, there was no small study bias observed in the Egger's test on overall atrial arrhythmias and AF analysis (p = .192 and p = .174, respectively). The quality assessment and bias risk assessment of the selected studies are shown in Figure 6.

4 | DISCUSSION

We conducted a meta-analysis of RCTs evaluating the addition of PWI to conventional ablation. The main finding from this meta-analysis is that the addition of PWI did not significantly improve efficacy in reducing arrhythmia recurrence.

In PAF, catheter ablation with radiofrequency or cryotherapy is known to be superior in maintaining sinus rhythm compared to
antiarrhythmic therapy. Nonetheless, therapy to maintain sinus rhythm in PeAF is less effective, and this reflects in weaker recommendations in the current guideline. The addition of left atrial roof line ablation was used by some investigators in an effort to improve clinical success, however increased risk of atrial flutter was noted on follow up (reference 14,18,19) An analysis of AF recurrence from the catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation (CABANA) trial suggested significantly reducing recurrence of any AF by 48% and symptomatic AF by 51%, when compared to drug therapy over 5 years of follow up. Although, the trial stipulates that all catheter ablation involved PVI, with additional ablation at the investigator’s discretion. Whether additional PWI would benefit AF recurrence remains controversial.

The posterior left atrial wall has a critical role in the initiation and maintenance of AF. Several anatomical and electrophysiologic properties increase the arrhythmogenicity of the posterior wall. Both the pulmonary veins and the posterior wall are embryologically derived from the same tissue (medialstinal myocardium). The posterior wall and PV also have shorter action potential durations and slower phase 0 upstroke velocity. The myocardial fibers’ orientation in the PV antra and posterior wall is distinct, allowing reentry from anisotropic conduction. Ganglionic plexi are most prevalent in the posterior wall of the left atrium. The posterior wall may be disproportionately affected by the pressure stress, and that has been correlated with low voltage and electrical scar. These areas of low voltage and electrical scar are predictive of poor outcomes after catheter ablation in persistent AF. The posterior wall has emerged as an additional target of ablation, especially in a patient undergoing ablation for persistent atrial fibrillation.

Our study suggested that the addition of PWI significantly decreased AF recurrence in PeAF but failed to decrease overall atrial arrhythmia recurrence. A study by Lim et al. demonstrated that PWI increased the incidence of reentrant tachycardia, which is likely attributable to posterior wall reconnection or even persistent epicardial connection (possibly due to the inability to achieve transmural ablations). We suspect that the decrease in AF recurrence is offset by an increase in the risk of reentrant flutter. Larger randomized controlled trials are needed to elucidate the magnitude of this phenomenon. Importantly, our study showed that the addition of PWI was not associated with increased acute/short-term complications. Whether increased thermal injury to the esophagus and risk of atrio-esophageal fistula is associated with the addition PWI remains unclear: this is related to the rare occurrence of this complication but invites caution.

### 4.1 Different criteria/techniques for posterior wall isolation

There is slight heterogeneity in PWI techniques among studies included in this meta-analysis, as outlined in Table 1. The key methods for PWI include a single ring and PVI plus box lesion set. There has also been emerging use of cryoablation with more recent
FIGURE 2  (A) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by a subgroup of PWI versus PVI without roof line and PWI versus PVI with roof line. (B) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by subgroup of PeAF and PeAF with PAF.
generations, of which the efficacy compared to radiofrequency (RF) ablation remains controversial. More data would be needed to elucidate the impact of cryoablation versus RF ablation on the finding from this meta-analysis.

### 4.2 Comparison with other meta-analyses

A recent meta-analysis by Thiyagaragjah et al., which includes 17 studies, evaluated the efficacy and safety of PWI during AF...
The study concluded that PWI could be achieved in a large portion of cases with satisfactory 12-month freedom of atrial arrhythmia. Of note, there were only three RCT comparing PWI with PVI directly, and the interpretation of combined conflicting data would be limited. Studies with cryoablation were excluded from the analysis.

---

| Study, year         | Vascular access injuries | Pericardial effusion | Pericarditis | Stroke/TIA |
|---------------------|--------------------------|----------------------|--------------|-------------|
| Aryana et al., 2020 | 55 0 54 1               |                      |              |             |
| Chilukuri et al., 2011 | 13 0 14 2               |                      |              |             |
| Lee et al., 2019    | 105 0 100 2             |                      |              |             |
| Pak et al., 2020    | 56 1 57 0               |                      |              |             |
| **Subtotal** (I-squared = 0.0%, p = 0.419) |                      | 1.02 (0.97, 1.07) | 1.13 (0.91, 1.41) |
| Aryana et al., 2020 | 54 1 55 0               |                      |              |             |
| Chilukuri et al., 2011 | 13 0 15 1               |                      |              |             |
| Lee et al., 2019    | 101 4 102 0             |                      |              |             |
| Lim et al., 2012    | 54 1 54 1               |                      |              |             |
| Pak et al., 2020    | 56 1 57 0               |                      |              |             |
| **Subtotal** (I-squared = 0.0%, p = 0.728) |                      | 0.98 (0.93, 1.03) | 1.06 (0.88, 1.26) |
| Aryana et al., 2020 | 54 1 55 0               |                      |              |             |
| Lee et al., 2019    | 104 1 100 2             |                      |              |             |
| Mun et al., 2012    | 52 0 49 3               |                      |              |             |
| Tamborero et al., 2009 | 59 1 58 2              |                      |              |             |
| **Subtotal** (I-squared = 1.8%, p = 0.383) |                      | 0.98 (0.93, 1.03) | 1.02 (0.98, 1.14) |
| Chilukuri et al., 2011 | 13 0 15 1               |                      |              |             |
| Lim et al., 2012    | 54 1 53 2               |                      |              |             |
| Mun et al., 2012    | 51 1 52 0               |                      |              |             |
| Tamborero et al., 2009 | 58 2 59 1          |                      |              |             |
| **Subtotal** (I-squared = 0.0%, p = 0.677) |                      | 0.98 (0.93, 1.04) | 1.00 (0.97, 1.03) |

**FIGURE 4** Forest plot of the risk of complications from PWI compared with controlled approaches

**FIGURE 5** Funnel plot of (A) PWI and overall atrial arrhythmia recurrences; B) PWI and AF recurrences
4.3 | Limitations

Our study has a few limitations. There was substantial heterogeneity among studies. Sensitivity analysis was undertaken. There is slight variation in techniques performed, patient population, and definitions of outcomes as outlined in Table 1. The number of participants included in the trial is relatively small and may lead to underpower in subgroup analyses. Moreover, there was a limitation of funnel plot interpretation from a small number of included studies.

5 | CONCLUSIONS

Our study showed that the addition of PWI to routine PVI in AF ablation significantly decreased AF recurrences after AF ablation, particularly in patients with PeAF. There were no significant differences in overall atrial arrhythmia recurrences with the addition of PWI to routine PVI, highlighting the increased risk of reentrant arrhythmias after this intervention.

ORCID
Chanavuth Kanitsoraphan © https://orcid.org/0000-0001-8222-550X

REFERENCES
1. Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am Coll Cardiol. 2020;75(25):3105–18.
2. Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015;17(3):370–8.
3. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74.
4. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316–24.
5. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275–444.
6. Tahir KS, Mounsey JP, Hummel JP. Posterior Wall isolation in atrial fibrillation ablation. J Innov Card Rhythm Manag. 2018;9(6):3186–94.

7. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812–22.

8. Pak HN, Park J, Park JW, Yang SY, Yu HT, Kim TH, et al. Electrical posterior box isolation in persistent atrial fibrillation changed to paroxysmal atrial fibrillation: a multicenter, prospective, randomized study. Circ Arrhythm Electrophysiol. 2020;13(9):e008531.

9. Chilukuri K, Scherr D, Dalal D, Cheng A, Spragg D, Nazarian S, et al. Conventional pulmonary vein isolation compared with the "box isolation" method: a randomized clinical trial. J Interv Card Electrophysiol. 2011;32(2):137–46.

10. Kim JS, Shin SY, Na JO, Choi CU, Kim SH, Kim JW, et al. Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: a prospective randomized clinical trial. Int J Cardiol. 2015;181:277–83.

11. Kim TH, Park J, Park JK, Uhm JS, Joung B, Hwang C, et al. Linear ablation in addition to circumferential pulmonary vein isolation (Dallas lesion set) does not improve clinical outcome in patients with paroxysmal atrial fibrillation: a prospective randomized study. Europace. 2015;17(3):388–95.

12. Lee JM, Shim J, Park J, Yu HT, Kim TH, Park JK, et al. The electrical isolation of the left atrial Posterior Wall in catheter ablation of persistent atrial fibrillation. JACC Clin Electrophysiol. 2019;5(11):1253–61.

13. Lim TW, Koay CH, See VA, McCall R, Chik W, Zecchin R, et al. Single-ring posterior left atrial (box) isolation results in a different mode of recurrence compared with wide antral pulmonary vein isolation on long-term follow-up: longer atrial fibrillation-free survival time but similar survival time free of any atrial arrhythmia. Circ Arrhythm Electrophysiol. 2012;5(5):968–77.

14. Mun HS, Joung B, Shim J, Hwang HJ, Kim JY, Lee MH, et al. Does additional linear ablation after circumferential pulmonary vein isolation improve clinical outcome in patients with paroxysmal atrial fibrillation: Prospective randomised study Heart. 2012;98(6):480–4.

15. Tamborero D, Mont L, Berruezo A, Matiello M, Benito B, Sitges M, et al. Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study. Circ Arrhythm Electrophysiol. 2009;2(1):35–40.

16. Aryana A, Di Biase L, Pujara DK, Baker HJ, Espinosa MA, de Asmundis C, et al. Long-term durability of posterior wall isolation using the cryoballoon in patients with persistent atrial fibrillation: a multicenter analysis of repeat catheter ablations. J Interv Card Electrophysiol. 2020;62:161–9.

17. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384(4):305–15.

18. Arbelo E, Guiti E, Ramos P, Bisbal F, Borras R, Andreu D, et al. Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study. J Am Heart Assoc. 2014;3(5):e000877.

19. Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation. 2005;112(24):3688–96.

20. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Melynky P, Hohnloser SH, et al. Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. J Physiol. 2003;551(Pt 3):801–13.

21. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the epicardial neural ganglionated subplexus in the human heart. Anat Rec. 2000;259(4):353–82.

22. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunaneeawitayakul B, Vasavakul T, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004;43(11):2044–53.

23. Verma A, Wazni OM, Marrouche NF, Martin DO, Kiliçaslan F, Minor S, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005;45(2):285–92.

24. Oakes RS, Badger TJ, Kholomovski EG, Akoum N, Burgon NS, Fish EN, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–67.

25. Thomas SP, Lim TW, McCall R, Seow SC, Ross DL. Electrical isolation of the posterior left atrial wall and pulmonary veins for atrial fibrillation: feasibility of and rationale for a single-ring approach. Heart Rhythm. 2007;4(6):722–30.

26. Cox JL, Canavan TE, Schuessler BB, Cain ME, Lindsay BD, Stone C, et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg. 1991;101(3):406–26.

27. Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW, et al. Current status of the maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg. 2000;12(1):15–9.

28. Saad EB, Slater C. Complete isolation of the left atrial Posterior Wall (box lesion) to treat longstanding persistent atrial fibrillation. J Arrhythm. 2014;7(4):1174.

29. Chen J, Off MK, Solheim E, Schuster P, Hoff PI, Ohm OJ. Treatment of atrial fibrillation by silencing electrical activity in the posterior inter-pulmonary-vein atrium. Europace. 2008;10(3):265–72.

30. Sanders P, Hocini M, Jais P, Sacher F, Hsu LF, Takahashi Y, et al. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome Eur Heart J. 2007;28(15):1862–71.

31. Mortsell D, Arbelo E, Dagres N, Brugada J, Larocche C, Trines SA, et al. Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace. 2019;21(4):581–9.

32. Hachem AH, Marine JE, Tahboub HA, Kandar S, Kanjwal S, Soni R, et al. Radiofrequency ablation versus cryoablation in the treatment of paroxysmal atrial fibrillation: a meta-analysis. Cardiol Res Pract. 2018;2018:6276241.

33. Thiagarajah A, Kadhmi K, Lau DH, Emami M, Linz D, Khokhar K, et al. Feasibility, safety, and efficacy of Posterior Wall isolation during atrial fibrillation ablation: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2019;12(8):e007005.

How to cite this article: Kanitsoraphan C, Rattanawong P, Techorueangwiwat C, Kewcharoen J, Mekritthikrai R, Prasitlumkum N, The efficacy of posterior wall isolation in atrial fibrillation ablation: A systematic review and meta-analysis of randomized controlled trials. J Arrhythmia. 2022;38:272–286. https://doi.org/10.1002/joa3.12698